Previous 10 | Next 10 |
Shares of Vir Biotechnology remain a dangerous play for bulls and bears alike. The highly volatile clinical-stage biotech company has posted the majority of its gains on single-day spikes. Long or short exposure is unsafe with near-term catalysts limited to likely 'priced in' news...
VIR did well with the prophylaxis studies but failed to impress with the hospitalisation data. Upcoming EUA and EMA reviews may be catalytic. However, the stock looks a bit too expensive for me right now. For further details see: Vir Biotechnology: Not Nearly Enough
– New combination trial of an RNA-targeted therapeutic candidate and an HBV immunotherapeutic candidate aimed at delivering a functional cure for chronic hepatitis B infection – Brii Biosciences (Brii Bio), Vir Biotechnology, Inc. (Nasdaq: VIR), and VBI Vaccines In...
Vir Biotechnology (NASDAQ: VIR) may be weeks away from commercializing its very first product. The clinical-stage biotech company and partner GlaxoSmithKline late last month requested Emergency Use Authorization (EUA) for their investigational COVID-19 treatment. In more goo...
The following slide deck was published by Vir Biotechnology, Inc. in conjunction with this event. For further details see: Vir Biotechnology (VIR) Presents At 20th Annual Needham Healthcare Conference - Slideshow
The European Medicines Agency ("EMA") has begun its review of GlaxoSmithKline (GSK) and Vir Biotechnology's (VIR) monoclonal antibody VIR-7831 for the early treatment of COVID-19 for patients at high risk of hospitalization.The EMA’s Committee for Human Medicinal Products will examine ...
Vir Biotechnology (VIR) announced the publication of new preclinical research highlighting the impact of additional cellular receptors on the clinical efficacy of monoclonal antibodies (mAbs) in COVID-19 infection.The company says that the research findings highlight the d...
GlaxoSmithKline (NYSE: GSK) , Vir Biotechnology (NASDAQ: VIR) , and Eli Lilly (NYSE: LLY) recently reported positive results from a phase 2 study evaluating a combination of Lilly's bamlanivimab with Vir's and Glaxo's VIR-7831 in treating COVID-19. In this Motley F...
Vir Biotechnology (VIR) announces the publication of new preclinical research highlighting novel mechanisms by which SARS-CoV-2 enters host cells and identifying how auxiliary receptors may impact the clinical efficacy of monoclonal antibodies ((mAbs)).The research highlights the distinct mec...
– Growing body of evidence suggests monoclonal antibodies that target a conserved epitope have the potential to be highly effective against SARS-CoV-2 and associated known mutations – – Newly identified cell surface proteins play a role in SARS-CoV-2 infectio...
News, Short Squeeze, Breakout and More Instantly...
Vir Biotechnology Inc. Company Name:
VIR Stock Symbol:
NASDAQ Market:
Vir Biotechnology Inc. Website:
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2024. Financial results will ...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
2024-07-08 10:47:03 ET BITX (BITX) BITX is trading DOWN for the last 4 days, and it at trading at $27.48 with volume of 3,908,355 and a one day change of $-0.37 (-1.33%). BITX has a 52-week low of 0.00 and a 52-week high of $0.00. The business's 50-day moving average price is $45.40...